For B2B teams building a peptide brand, WUMO supports finished lyophilized peptide vials under your own label --
peptide sourcing, vial filling, custom labels and packaging, and the quality documentation buyers ask for before
they order.
A growing share of B2B buyers need more than bulk peptide raw material. They may require lyophilized peptide vials,
defined fill quantities, custom labels and secondary packaging, together with batch-specific documentation for
procurement, research supply, distribution, or product-development programs.
WUMO supports B2B private-label lyophilized peptide vial projects from sample or pilot evaluation through batch
production. Typical production MOQ starts from 1,000 vials per SKU, depending on the peptide, fill quantity, vial
configuration, label, and packaging scope. Project scope can include peptide sourcing, defined fill quantities,
lyophilization coordination, custom vial labels, outer packaging, and agreed batch documentation such as COA, HPLC,
LC-MS, sterility, and bacterial endotoxin test reports where applicable. Exact scope is confirmed before quotation and
production.
Scope
What WUMO Provides for Private Label Vials
Support is reviewed against the peptide, format, packaging scope, documentation requirements, and destination market for each project.
Peptide sourcing
Research-series lyophilized peptides -- with cosmetic peptides available as a cross-reference -- sourced against a defined specification, purity threshold, and documentation scope.
Lyophilized vial preparation
Project-based vial preparation including defined fill quantity, vial size, and stopper and crimp configuration, with lyophilization coordination. Manufacturing conditions, testing scope, and available documentation are confirmed for the specific peptide and project.
Custom labels
Your brand identity applied to the vial label, with label content and artwork confirmed against the project specification before production.
Outer packaging
Outer box format, kit contents, and packaging specification for a finished private label presentation.
Documentation package
COA, sterility report, and bacterial endotoxin (LAL) report where applicable, alongside HPLC and LC-MS files, prepared for procurement and import review.
Pilot-to-production coordination
A pilot sample run to evaluate quality and packaging, followed by a production run once the specification and documents are confirmed.
MOQ & Packaging
Minimum Order Quantity by Stage
MOQ for finished vials is driven by lyophilization run setup, fill amount, labels, and packaging -- not quantity alone. The figures below are typical starting points and are confirmed per project.
Stage
Typical quantity
Purpose
Sample evaluation
Sample vials on request
Assess peptide quality, fill amount, label artwork, and packaging before committing to a production run
Production run
From 1,000 vials per SKU
Batch production at the confirmed specification; lyophilization run setup, labels, and packaging are shared across the batch
Multi-SKU program
Confirmed per project
Buyers building a brand line across several peptides can discuss combined planning, packaging, and documentation
Process
From Pilot Sample to Production
Projects that confirm the specification and documentation scope before production tend to move faster and encounter fewer surprises between order and delivery.
Step
What is confirmed
Why it matters
1. Project brief
Target peptide(s), fill amount, vial format, label and packaging direction, destination market, and documentation needs
A clear brief lets WUMO confirm feasibility and quote the right project rather than an assumed one
2. Sample or pilot evaluation
Depending on project scope, evaluation may use available sample vials, representative packaging samples, or a project-specific pilot arrangement
Reviewing quality, fill, packaging, or documentation points before commercial batch production reduces the risk of surprises
3. Specification & document sign-off
Confirmed fill amount, vial and packaging specification, label artwork, and documentation scope (COA, sterility, endotoxin)
Locking the specification and documents before production avoids mid-run changes that add cost and lead time
4. Production run
Batch production at the agreed MOQ, with quality documentation prepared for the batch
A confirmed specification and document package keep the production run and the delivered goods aligned
5. Documentation & shipment
Batch documentation, packing information, and available shipment documents prepared according to the confirmed project scope
Import requirements remain dependent on the product, declared use, destination market, and applicable local regulations
Quality Documentation for Finished Vials
Beyond a COA, buyers of finished peptide vials increasingly ask for sterility and endotoxin testing. The documentation set below can accompany qualified finished vial projects; availability of each document depends on the product and batch.
Document
What it helps verify
Notes
Certificate of Analysis (COA)
Identity, HPLC purity, appearance, and batch results against specification
Standard for finished vial orders
Sterility Report
Sterility testing result for the filled vial batch
Provided for qualified finished vial projects, subject to product and batch
Bacterial Endotoxin (LAL) Report
Endotoxin level of the filled vial batch
Provided for qualified finished vial projects, subject to product and batch
HPLC Chromatogram
Visual purity data and peak profile from the production batch
Available where the project or destination requires batch-level purity data
LC-MS Report
Observed molecular mass and its consistency with the expected peptide molecular mass
Used together with other analytical data to support peptide identity
Packaging & Label Specification
Vial size, fill amount, label format, and outer box configuration
Confirmed before production for private label projects
For batch-level review, buyers should confirm that the batch or sample identification on each report can be traced to
the supplied material or finished vial batch. A test report is most useful when its sample identity, test method,
result, specification, and batch relationship are clear.
Fill quantity and peptide content are not automatically demonstrated by an HPLC purity percentage. Purity describes the
analyzed sample under the test method; the appropriate approach for verifying vial fill quantity and peptide content
depends on the peptide, formulation matrix, and agreed specification.
What to Prepare for a Project Discussion
Product & format
Target peptide(s) for the private label line
Fill amount per vial and vial size
Primary use: research / laboratory supply (cosmetic peptides available as a cross-reference)
Branding & packaging
Brand name and label artwork status
Outer packaging format and kit contents
Any market-specific label text you need to include
Destination country and any import documentation needs
Frequently Asked Questions
What does WUMO provide for a peptide vial OEM or private label project?
WUMO supports B2B teams that want finished lyophilized peptide vials under their own brand. Scope typically covers peptide sourcing, lyophilized vial filling, custom label and outer packaging, and the documentation package needed for procurement and import review. Support is provided for qualified research and B2B supply projects.
What is the minimum order quantity for private label peptide vials?
Production MOQ is typically from 1,000 vials per SKU, because lyophilization run setup, labels, and packaging tooling are shared across the batch. Before a production run, sample vials can be provided so a buyer can evaluate quality, fill amount, labels, and packaging. Exact MOQ depends on fill amount, vial format, and packaging scope and is confirmed per project.
Can we use our own brand, labels, and packaging?
Yes. Private label projects can use your brand identity on the vial label and outer packaging. Label content, artwork, and packaging format are confirmed against the project specification before production. Buyers are responsible for the regulatory text and claims appropriate to their own market.
What quality documentation comes with finished vials?
The documentation set for finished vial projects can include a Certificate of Analysis (COA), a sterility report, and a bacterial endotoxin (LAL) report, alongside standard technical files such as HPLC and LC-MS where applicable. Availability of each document depends on the product and batch and is confirmed for qualified projects.
How does the sample-to-production process work?
Projects generally start with a sample or pilot evaluation -- using available sample vials, representative packaging samples, or a project-specific pilot arrangement depending on scope -- so the buyer can review the peptide, fill amount, labels, and packaging. Once the specification and documentation scope are confirmed, the project moves to a production run at the agreed MOQ. Confirming the specification before production reduces revision rounds and avoids mid-run changes that add cost and lead time.
Is HPLC purity enough to verify a finished peptide vial?
No. HPLC purity describes the relative chromatographic purity of the analyzed sample under the test method. It does not by itself establish vial fill quantity, sterility, bacterial endotoxin level, or full sequence confirmation. A finished vial is better assessed against the full set of agreed reports -- COA, HPLC, LC-MS, and, where applicable, sterility and bacterial endotoxin -- with each report traceable to the supplied batch.
Which peptides can be filled into private label vials?
Vial projects can cover cosmetic peptides as well as research-series lyophilized peptides, subject to product policy, buyer qualification, and destination market. WUMO can review whether a specific peptide fits a private label vial project during the initial project discussion.
Start an OEM / Private Label Peptide Vial Project
Share your target peptide, fill amount, packaging direction, quantity, and documentation needs. WUMO will review the project before confirming the next step.
OEM / Private Label Vial Project
Tell us the peptide, fill amount, brand and packaging direction, target quantity, and the documents you need (COA, sterility, endotoxin). WUMO will review the project assumptions before confirming the next step.
If some details are not final yet, include what you have and mark the open points.